IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)

Arthritis Research and Therapy

Volumn 19, Issue 1, 2017, Pages

  Oke, Vilija ^a   Brauner, Susanna ^a   Larsson, Anders ^b   Gustafsson, Johanna ^a   Zickert, Agneta ^a   Gunnarsson, Iva ^a   Svenungsson, Elisabet ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Interferon ; Interferon 1; Interleukin 17; Interleukin 23; IP 10; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; CREATININE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 17; INTERLEUKIN 29; LA ANTIBODY; PHOSPHOLIPID ANTIBODY; RO ANTIBODY; CYTOKINE; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ARTICLE; BONE INJURY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEROLOGY; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; ADULT; AGED; CROSS-SECTIONAL STUDY; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; TH17 CELL;

ADULT; AGED; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TH17 CELLS;

EID: 85021089484     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-017-1344-7     Document Type: Article

References (45)

1. Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14:R46. doi: 10.1186/ar3759.
2. Vikerfors A, Johansson AB, Gustafsson JT, Jönsen A, Leonard D, Zickert A, et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford). 2013;52:501-9. doi: 10.1093/rheumatology/kes252.
3. Kvarnström M, Dzikaite-Ottosson V, Ottosson L, Gustafsson JT, Gunnarsson I, Svenungsson E, et al. Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus. Lupus. 2013;22:477-85. doi: 10.1177/0961203313479420.
4. Rönnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991;115:178-83.
5. Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75:2014-21. doi: 10.1136/annrheumdis-2015-208140.
6. Rönnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013;25:248-53. doi: 10.1097/BOR.0b013e32835c7e32.
7. Kirou KA, Lee C, George S, Louca K, Peterson MGE, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491-503. doi: 10.1002/art.21031.
8. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9:664-71.
9. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MGE, et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:3958-67. doi: 10.1002/art.20798.
10. Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41:D1040-6. doi: 10.1093/nar/gks1215.
11. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y. Interferon-λ1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther. 2011;13:R88. doi: 10.1186/ar3363.
12. Blazek K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, et al. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J Exp Med. 2015;212:845-53. doi: 10.1084/jem.20140995.
13. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63-8. doi: 10.1038/ni873.
14. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol. 2012;189:2735-45. doi: 10.4049/jimmunol.1102038.
15. H17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med. 2013;5:204ra129. doi: 10.1126/scitranslmed.3006245.
16. Zahn S, Rehkämper C, Kümmerer BM, Ferring-Schmidt S, Bieber T, Tüting T, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131:133-40. doi: 10.1038/jid.2010.244.
17. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010;84:5670-7. doi: 10.1128/JVI.00272-10.
18. Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol. 2015;16:7. doi: 10.1186/s12865-015-0070-7.
19. Rose T, Grützkau A, Hirseland H, Huscher D, Dähnrich C, Dzionek A, et al. IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2013;72:1639-45. doi: 10.1136/annrheumdis-2012-201586.
20. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009;60:3098-107. doi: 10.1002/art.24803.
21. Merrill JT, Furie R, Werth VP, Khamashta M, Drappa J, Wang L, et al. Anifrolumab reduces disease activity in multiple organ domains in moderate to severe systemic lupus erythematosus (SLE) [abstract THU0295]. Ann Rheum Dis. 2016;75 Suppl 2:293. doi: 10.1136/annrheumdis-2016-eular.4033.
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
23. Castrejón I, Tani C, Jolly M, Huang A, Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S85-95.
24. Liang MH, Socher SA, Roberts WN, Esdail JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988;31:817-25.
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35:630-40.
26. Urowitz MB, Gladman DD. Measures of disease activity and damage in SLE. Baillieres Clin Rheumatol. 1998;12:405-13.
27. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol. 1999;26:490-7.
28. Klahr S. The modification of diet in renal disease study. N Engl J Med. 1989;320:864-6. doi: 10.1056/NEJM198903303201310.
29. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35:248-54.
30. Gustafsson JT, Gunnarsson I, Källberg H, Pettersson S, Zickert A, Vikerfors A, et al. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1537-43. doi: 10.1136/annrheumdis-2013-205159.
31. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
32. Yin Z, Huang J, He W, Cao Z, Luo X, Zhang C, et al. Serum level of eight cytokines in Han Chinese patients with systemic lupus erythematosus using multiplex fluorescent microsphere method. Cent Eur J Immunol. 2014;39:228-35. doi: 10.5114/ceji.2014.43728.
33. Manson JJ, Ma A, Rogers P, Mason LJ, Berden JH, van der Vlag J, et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther. 2009;11:R154. doi: 10.1186/ar2831.
34. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev. 2012;12:97-106. doi: 10.1016/j.autrev.2012.07.002.
35. Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol. doi: 10.1016/j.clim.2016.04.010. In press.
36. Gerhardsson J, Sundelin B, Zickert A, Padyukov L, Svenungsson E, Gunnarsson I. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. Arthritis Res Ther. 2015;17:109. doi: 10.1186/s13075-015-0614-5.
37. Jolly M, Francis S, Aggarwal R, Mikolaitis RA, Niewold TB, Chubinskaya S, et al. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus. 2014;23:881-8. doi: 10.1177/0961203314530793.
38. Kuan WP, Tam LS, Wong CK, Ko FWS, Li T, Zhu T, et al. CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol. 2010;37:257-64. doi: 10.3899/jrheum.090769.
39. Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther. 2009;11:R186. doi: 10.1186/ar2878.
40. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One. 2012;7, e37000. doi: 10.1371/journal.pone.0037000.
41. Niewold TB, Hua J, Lehman TJA, Harley JB, Crow MK. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8:492-502. doi: 10.1038/sj.gene.6364408.
42. Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22:146-53. doi: 10.1038/nm.4027.
43. Mordstein M, Michiels T, Staeheli P. What have we learned from the IL28 receptor knockout mouse? J Interferon Cytokine Res. 2010;30:579-84. doi: 10.1089/jir.2010.0061.
44. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol. 2013;93:377-85. doi: 10.1189/jlb.0812395.
45. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:2951-62. doi: 10.1002/art.22044.